Nexalin Hosts Live Investor Webinar and Q&A

Webinar to provide updates on the advanced neuromodulation company's progress

Apr. 14, 2026 at 2:23pm

Got story updates? Submit your updates here. ›

A highly polished, minimalist studio photograph featuring a sleek, modern medical device or instrument in a monochromatic color palette, conceptually representing Nexalin's advanced neuromodulation technology.Nexalin's innovative neuromodulation technology takes center stage in this elegant studio still life, hinting at the company's progress and potential impact.Today in Orlando

Nexalin Technology, Inc., a Nasdaq-listed advanced neuromodulation company, will host an exclusive live investor webinar and Q&A session on April 21, 2026 at 4:15 p.m. ET. The webinar will be hosted by RedChip Companies and is open to the public.

Why it matters

As a publicly traded company, Nexalin regularly engages with investors through webinars and other events to provide updates on its business and technology developments. These sessions allow the company to share its progress, answer questions, and build transparency with the investment community.

The details

The webinar will feature presentations from Nexalin's management team and provide an opportunity for investors to ask questions. Topics are expected to include the company's latest advancements in its neuromodulation technology, product pipeline, and market opportunities.

  • The webinar will take place on April 21, 2026 at 4:15 p.m. ET.

The players

Nexalin Technology, Inc.

A Nasdaq-listed advanced neuromodulation company developing innovative therapies for mental health conditions.

RedChip Companies

A leading small-cap research and financial public relations firm that will be hosting the Nexalin investor webinar.

Got photos? Submit your photos here. ›

What’s next

Investors can register for the webinar through the RedChip Companies website.

The takeaway

Nexalin's upcoming investor webinar demonstrates the company's commitment to maintaining open communication with its shareholders as it continues to advance its neuromodulation technology and product pipeline.